Shionogi to buy Sciele for $1.4 billion
This article was originally published in Scrip
Shionogi has signed a definitive agreement to buy the US firm Sciele Pharmafor $1.4 billion. The move aims to boost the mid-sized Japanese firm's presence and marketing capability in the key US market, which it sees as critical to mid-term growth.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.